OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.otsuka-us.com

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

First Posted Date
2011-08-26
Last Posted Date
2015-10-29
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
218
Registration Number
NCT01423916
Locations
🇺🇸

Otsuka Investigational Site, Austin, Texas, United States

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-08-26
Last Posted Date
2014-01-15
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
45
Registration Number
NCT01423903

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-08-17
Last Posted Date
2021-10-07
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
83
Registration Number
NCT01418352

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-08-17
Last Posted Date
2021-10-07
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
135
Registration Number
NCT01418339

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-08-15
Last Posted Date
2021-10-07
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
170
Registration Number
NCT01416441

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-07-20
Last Posted Date
2017-05-10
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
1044
Registration Number
NCT01397786

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-07-15
Last Posted Date
2016-04-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
202
Registration Number
NCT01395017

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-07-13
Last Posted Date
2015-11-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
674
Registration Number
NCT01393613
© Copyright 2024. All Rights Reserved by MedPath